USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

Market Overview ScreenersIndustriesCompanies Community Investment Grader

US Market Open: Feb 9, 13:17 PM 2012

NYSE 8087.37 4.39 Index Moved Up

NASDAQ 2925.62 9.76 Index Moved Up

and more..

sponsered by

Processing
Collecting necessary data for SLXP and HLF...

Asset Comparison and Correlation

View All Portfolios

More Actions
- Select Assests
- Optimize Portfolio
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatilities
- Import Equities
- Search Equities
- Filter Tops

Salix Pharmaceuticals Ltd. and

Herbalife Ltd. Common Stock

Volatility

Matrix

Run Correlation

Diversification

Modest diversification

Overlapping area represents amount of risk that can be diversified away by holding Salix Pharmaceuticals Ltd. and Herbalife Ltd. Common Stock in the same portfolio (assuming nothing else is changed)

Optimize

Correlation Coefficient

0.24

Parameters

Time Period	1 Month [change]
Direction	Positive
Strength	Very Weak
Accuracy	91.3%
Values	Daily Returns

Suggest

48.9

Intraday

One Month

^(0.32)

0.65%

SLXP

NASDAQ

Salix Pharmaceuticals Ltd.

P/E	37.86	P/B Ratio	6.06
Open	49.47	Day Low	48.80
Market Cap	2.892B	Volume	112158
Last Close	49.22	Short Ratio	7.80
Last Traded	2/9/2012	Year High	50.28
Percent Change	0.65%	EBITDA	142.7M
Year Low	25.64	Absolute Change	0.32
Book Value	8.127	EPS	1.30
PEG Ratio	0.94	Day High	49.8084
Target Price	54.53	Current EPS	1.30
This Year EPS	2.55	Next Year EPS	2.79
Current PE	37.86	This Year PE	19.30
Next Year PE	17.64	Dividend	Not Applicable

Illumina's Board Unanimously Rejects Roche's Offer; Shire Announces FDA ...

BioMedReports (subscription) - Feb 8, 2012

By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on February 7, 2012.

2012-02-07

Salix Pharmaceuticals Announces FDA Granting of Priority Review Designation ...

MarketWatch (press release) - Feb 7, 2012

RALEIGH, NC, Feb 07, 2012 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. /quotes/zigman/87125/quotes/nls/slxp SLXP -0.25% today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation for the Company's New Drug ...

Salix Pharmaceuticals Announces FDA Priority Review Designation for Crofelemer NDA
- NCTechNews (press release)

2012-02-07

Salix Pharmaceuticals Announces FDA Granting Of Priority Review Designation For Crofelemer NDA For Treatment Of Diarrhea

Reuters Key Development - Feb 7, 2012

2012-02-07

Salix Pharmaceuticals Crosses Above its 10-day MA (SLXP)

Financial News Network Online - Jan 31, 2012

Salix Pharmaceuticals (NASDAQ:SLXP) shares have crossed bullishly above their 10-day moving average of $46.89 on a volume of 132K shares.

2012-01-31

Salix Scores with Oral Relistor

2011-12-27

Salix Pharmaceuticals (SLXP): Zacks Rank Buy

2011-12-19

Zacks Bull and Bear of the Day Highlights: Salix Pharmaceuticals, Montpelier Re Holdings, Wal-Mart, Macy's and Best Buy

2011-11-28

59.19

Intraday

One Month

^(0.65)

1.09%

HLF

NYSE

Herbalife Ltd. Common Stock

P/E	19.33	P/B Ratio	13.45
Open	59.78	Day Low	59.01
Market Cap	6.885B	Volume	388921
Last Close	59.84	Short Ratio	3.70
Last Traded	2/9/2012	Year High	63.40
Percent Change	1.09%	EBITDA	605.5M
Year Low	33.13	Absolute Change	0.65
Book Value	4.449	EPS	3.095
PEG Ratio	1.34	Day High	59.86
Target Price	70.17	Current EPS	3.095
This Year EPS	3.18	Next Year EPS	3.49
Current PE	19.33	This Year PE	18.82
Next Year PE	17.15	Dividend	0.625
Dividend Yield	1.04	Dividend Date	Nov 28

HSBC Business Thinking: businesses join forces to take on the world

2011-03-31

HSBC Business Thinking: businesses join forces to take on the world

2011-03-30

NTRR Begins Clinical Trials of Breakthrough Weight-Loss Formula

EON: Enhanced Online News (press release) - 16 hours ago

TAMPA, Fla.--(EON: Enhanced Online News)--Neutra Corp. (OTCBB: NTRR), an emerging nutraceuticals provider, is excited to announce that clinical trials are now underway on its debut weight-loss supplement, Pure Plus.

2012-02-08

NTRR Begins Clinical Trials of Breakthrough Weight-Loss Formula

Business Wire (press release) - Feb 8, 2012

TAMPA, Fla.--(BUSINESS WIRE)--Neutra Corp. (OTCBB: NTRR), an emerging nutraceuticals provider, is excited to announce that clinical trials are now underway on its debut weight-loss supplement, Pure Plus.

2012-02-08

NTRR To Begin Clinical Trials Of Pure Plus This Week

TheStreet.com (press release) - Feb 6, 2012

By Business Wire 02/06/12 - 05:00 AM EST Neutra Corp. (OTCBB: NTRR), an emerging nutraceuticals provider, expects to begin clinical trials of its eagerly anticipated new all-natural weight-loss supplement as early as this week when the company's first ...

2012-02-06

Top 10 Best-Rated Personal Services Stocks: NUS, XRS, NTRI, STEI, DVOX, SCI ...

China Analyst - Feb 3, 2012

Below are the top 10 best-rated Personal Services stocks, based on the percentage of positive ratings by brokerage analysts. One Chinese company (XRS) is on the list.

2012-02-03

Zacks Investment Ideas feature highlights: Herbalife, Kadant and Wyndham Worldwide

2012-01-15

3 Earnings Season All-Stars

2012-01-12

Herbalife Ltd. (HLF): Zacks Rank Buy

2012-01-03